This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
CEO buying at Arch Biopartners (ARCH)
Richard Gabriel Muruve, CEO, Director and 10% Holder, acquired 480,923 Common Shares on a direct ownership basis at a price of $1.040 through a prospectus or prospectus exempt offering on November 18th, 2025. This represents a $500,160 investment into the company's shares and an account share holdings change of 5.3%.
Let the insiders guide you to opportunity at Canadianinsider.com.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
